I agree that this site is using cookies. You can find further informations here.
X
Hubert, Dominique
1165  results:
OpenAccess-fulltext X
?
1

Use of 2,6-diaminopurine as a potent suppressor of UGA prem..:

Leroy, Catherine ; Spelier, Sacha ; Essonghe, Nadège Charlene...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ymthe.2023.01.014.  , 2023
Link: https://hal.science/hal-..
 
?
2

Use of 2,6-diaminopurine as a potent suppressor of UGA prem..:

Leroy, Catherine ; Spelier, Sacha ; Essonghe, Nadège Charlene...
10.1016/j.ymthe.2023.01.014.  , 2023
Link: https://hdl.handle.net/2..
 
?
3

Use of 2,6-diaminopurine as a potent suppressor of UGA prem..:

Leroy, Catherine ; Spelier, Sacha ; Essonghe, Nadège Charlene...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ymthe.2023.01.014.  , 2023
Link: https://hal.science/hal-..
 
?
4

High Susceptibility for Cystic Fibrosis Human Airway Gland ..:

Tabary, Olivier ; Escotte, Sandie ; Couetil, Jean, Paul...
info:eu-repo/semantics/altIdentifier/doi/10.4049/jimmunol.164.6.3377.  , 2023
Link: https://hal.science/hal-..
 
?
5

Use of 2,6-diaminopurine as a potent suppressor of UGA prem..:

Leroy, Catherine ; Spelier, Sacha ; Essonghe, Nadège Charlene...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ymthe.2023.01.014.  , 2023
Link: https://hal.science/hal-..
 
?
6

High Susceptibility for Cystic Fibrosis Human Airway Gland ..:

Tabary, Olivier ; Escotte, Sandie ; Couetil, Jean, Paul...
info:eu-repo/semantics/altIdentifier/doi/10.4049/jimmunol.164.6.3377.  , 2023
Link: https://hal.science/hal-..
 
?
7

Real-World Long-Term Ivacaftor for Cystic Fibrosis in Franc..:

Hubert, Dominique ; Marguet, Christophe ; Benichou, Jacques...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589905/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
8

Correction to: Real-World Long-Term Ivacaftor for Cystic Fi..:

Hubert, Dominique ; Marguet, Christophe ; Benichou, Jacques...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589946/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
9

Clinical response to lumacaftor-ivacaftor in patients with ..:

Burgel, Pierre-Régis ; Durieu, Isabelle ; Chiron, Raphaël...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jcf.2020.06.012.  , 2020
Link: https://hal.sorbonne-uni..
 
?
10

Clinical response to lumacaftor-ivacaftor in patients with ..:

Burgel, Pierre-Régis ; Durieu, Isabelle ; Chiron, Raphaël...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jcf.2020.06.012.  , 2020
Link: https://hal.sorbonne-uni..
 
?
11

Clinical response to lumacaftor-ivacaftor in patients with ..:

Burgel, Pierre-Régis ; Durieu, Isabelle ; Chiron, Raphaël...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jcf.2020.06.012.  , 2020
Link: https://hal.sorbonne-uni..
 
?
12

Clinical response to lumacaftor-ivacaftor in patients with ..:

Burgel, Pierre-Régis ; Durieu, Isabelle ; Chiron, Raphaël...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jcf.2020.06.012.  , 2020
Link: https://hal.sorbonne-uni..
 
?
13

Clinical response to lumacaftor-ivacaftor in patients with ..:

Burgel, Pierre-Régis ; Durieu, Isabelle ; Chiron, Raphaël...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jcf.2020.06.012.  , 2020
Link: https://hal.sorbonne-uni..
 
?
14

Clinical response to lumacaftor-ivacaftor in patients with ..:

Burgel, Pierre-Régis ; Durieu, Isabelle ; Chiron, Raphaël...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jcf.2020.06.012.  , 2020
Link: https://hal.sorbonne-uni..
 
?
15

Clinical response to lumacaftor-ivacaftor in patients with ..:

Burgel, Pierre-Régis ; Durieu, Isabelle ; Chiron, Raphaël...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jcf.2020.06.012.  , 2020
Link: https://hal.sorbonne-uni..
 
1-15